|Bid||0.0000 x 1400|
|Ask||0.9300 x 900|
|Day's Range||0.8500 - 0.9361|
|52 Week Range||0.8500 - 0.9361|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 31, 2019 - Aug 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN. LONDON, April 23, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (MPH.L), a clinical stage, UK-based, biopharmaceutical company focused on rare diseases, announces that the merger with OncoMed Pharmaceuticals, Inc. ("OncoMed" NASDAQ:OMED) announced on 5 December 2018 has today completed.
Mereo BioPharma Group plc (MPH.L), a clinical stage, UK-based, biopharmaceutical company focused on rare diseases, announces today that stockholders of OncoMed (OMED) have approved the transactions contemplated by the merger agreement dated 5 December 2018 between Mereo, OncoMed and certain other parties thereto (the "Merger Agreement"), pursuant to which OncoMed will become a wholly-owned indirect subsidiary of Mereo (the "Merger"), at a meeting of OncoMed's stockholders duly convened and held on 17 April 2019.
OncoMed Pharmaceuticals, Inc. (“OncoMed”) (OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that its board of directors declared a one-time special dividend in the form of a contractual right to receive, on a pro rata basis, cash payments from OncoMed upon the actual receipt by OncoMed or its affiliates of certain contingent cash amounts in the future following the exercise by Celgene Corporation or certain of Celgene Corporation’s affiliates (together, “Celgene”) of the exclusive option granted by OncoMed to Celgene in relation to OncoMed’s etigilimab product. More specifically, if a specified approval or sales milestone is achieved or if royalties are paid by Celgene to OncoMed or its affiliates in respect of the etigilimab product (in each case, pursuant to a license agreement to be entered into by OncoMed and Celgene upon Celgene’s exercise of its exclusive option in relation to OncoMed’s etigilimab product (the “TIGIT License Agreement”)), the special dividend will entitle stockholders to receive an amount in cash equal to such holder’s pro rata portion of any cash payments made by Celgene and actually received by OncoMed or its affiliates in respect thereof, net of any tax and reasonable costs and expenses incurred by OncoMed or its affiliates in connection with such payments.
REDWOOD CITY, Calif., March 07, 2019 -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel.
Biotech companies' reasons differ for 600 job cuts over the past few months, but the numbers are jarring for an industry at the intersection of a strong cash position and groundbreaking science.
In the midst of a dramatic start to December, market news has taken a backseat to a surge in volatility and reactionary trading. However, volatility doesn’t stop the headlines, and there’s still big catalysts ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 6) Gritstone Oncology Inc (NASDAQ: GRTS ) Down In The Dumps ...
OncoMed's clinical trial failures prevented the Redwood City company from achieving the financial promise of deals with Celgene, Bayer and GlaxoSmithKline. Now a London company is reverse merging with it to get its NASDAQ listing and Peninsula facility.
Mereo BioPharma Group plc (MPH.L) (“Mereo”, the “Company” or the “Group”), the clinical stage UK based biopharmaceutical company focused on rare diseases, and OncoMed Pharmaceuticals, Inc. (OMED) (“OncoMed”), a NASDAQ listed oncology-focused clinical stage biopharmaceutical business, today announce the proposed combination of Mereo and OncoMed (the “Transaction”). The Transaction has been unanimously approved by the Board of Directors of each company.
NEW YORK, Nov. 15, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
OncoMed Pharmaceuticals, Inc. (OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced initial results from the Phase 1a dose escalation portion of a Phase 1a/b trial of etigilimab, the company’s anti-TIGIT antibody. OncoMed’s anti-TIGIT checkpoint inhibitor candidate is an IgG1 monoclonal antibody which binds to the human TIGIT receptor on T-cells with a goal of improving the activation and effectiveness of T-cell and NK cell tumor-killing activity. The initial results from the Phase 1a dose escalation portion of the Phase 1a/b trial included data from 18 patients with a variety of late stage metastatic cancers including colorectal, endometrial, pancreatic, among others, who were treated with etigilimab at doses ranging from 0.3 to 20 mg/kg every other week.
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Read More...
The Redwood City, California-based company said it had net income of 16 cents per share. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
-Company continues enrollment in Phase 1b navicixizumab trial following encouraging single agent and interim combination results in ovarian cancer; -Prepares for presentation.
Anyone researching OncoMed Pharmaceuticals Inc (NASDAQ:OMED) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and thereRead More...
OncoMed (OMED) delivered earnings and revenue surprises of 56.52% and -8.28%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Redwood City, California-based company said it had a loss of 10 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...